We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Inspection Prompts Compounding Pharmacy to Recall Products, Shut Down Operations

FDA Inspection Prompts Compounding Pharmacy to Recall Products, Shut Down Operations

September 5, 2014

Martin Avenue Pharmacy is recalling all of its unexpired sterile preparations and stopping production of sterile drugs after FDA investigators discovered contaminated products and evidence of poor quality control.

During a June to July inspection of the compounding pharmacy’s Naperville, Ill., facility, the FDA observed a black particle in a vial of an injectable drug mix containing papaverine and phentolamine.

The agency also found problems with the pharmacy’s procedures designed to prevent microbial contamination. For instance, personnel who produce sterile drug products aren’t monitored for microbial contamination, according to a Form 483 issued July 21.

Martin Avenue also rinses its sterilized glass beakers and stir bars with “purified” water produced from municipal tap water, however the agency hasn’t tested the water to determine its purity, bioburden or pyrogen levels, the FDA said. In addition, the compounder didn’t conduct stability testing on two types of human injectable sterile drugs: hyaluronidase injectable solution and methylcobalamin.

The pharmacy emphasized that it hasn’t received any complaints of patient risks from the recalled products, but noted that if a compounded drug loses sterility it could infect a patient. The company’s non-sterile preparations aren’t affected by the recall.

The pharmacy said it decided to do the recall and cease production out of an “abundance of caution.”

The FDA has stepped up inspections and enforcement actions on compounders after a November 2013 law enhanced its powers over larger pharmacies. Quality experts have said that a barrage of warning letters to compounders has forced the industry to take FDA enforcement more seriously.
Martin Avenue declined to comment further.

Make sure your products are sterile! Help avoid a costly recall by ordering Manufacturing Sterile Products to Meet EU and FDA Guidelines today!

Pharmaceuticals Quality Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing